Abstract
This exploratory field study explores the safety and efficacy of an optimized dose of a modified grass allergen subcutaneous immunotherapy (SCIT) product (1.0 ml) with microcrystalline tyrosine (MCT) and monophosphoryl lipid A (MPL) adjuvant system for the treatment of allergic rhinoconjunctivitis (ARC) due to grass pollen.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
